Key Takeaways
- Battery chemicals reset, base business steady: FY26 battery revenue slashed to ₹30–40 crore from ₹300 crore on delayed approvals and demand, but the standalone base business ₹850 crore plan is on track.
- FEOC restrictions are the demand catalyst: China’s November 8th export curbs shook global customers, who are now urgently seeking non-Chinese electrolyte salt supply, positioning Neogen as the cheapest outside China.
- Morita JV de-risks the technology bet: The Indo-Japan joint venture gives customers confidence in quality and reliability, accelerating sample approvals and commercial discussions with three to four large consumers.
- Fire aftermath still weighing on profits: Higher insurance premiums, job-work costs, and debt taken to rebuild Dahej before the final insurance payout compressed PAT to ₹3 crore; the loss-of-profit claim won’t land until FY27.
- What to watch next quarter: Whether electrolyte salt final approvals arrive in Q4 FY26 as guided, the pace of customer offtake ramp-up, and receipt of the stock-related insurance claim.
Battery Chemicals: The Big Guidance Reset
- Electrolyte demand delayed, not lost: Approvals took longer than expected and Indian gigafactory ramp-up (Ola, Exide) shifted right; management now sees stronger electrolyte demand only from Q4 FY26 onward.
- FY26 battery revenue slashed: The earlier ₹300 crore target is replaced by ₹30–40 crore, entirely dependent on Q4 electrolyte offtake.
- FY27 target still ambitious at ₹400–500 crore: This hinges on salt final approvals in Q4 FY26 or Q1 FY27, US customers switching from Chinese supply, and Indian cell manufacturing beginning in earnest.
- FY29 full-utilization math unchanged: Management still targets ₹2,400–2,900 crore from battery chemicals at full utilization, with FY28 crossing ₹1,000 crore.
- Greenfield facility on track for H1 FY27: Mechanical completion expected by end-CY2025, trial production to follow, with commercial electrolyte production in H1 FY27 and electrolyte salt in H2 FY27.
Harin Kanani: "Based on today's situation, as I explained earlier, since our electrolyte demand has been lower, although we are ready and we took longer time for getting approval, we are expecting it longer. So this year, we would not be able to achieve INR 300 crore."
The FEOC Opportunity & Competitive Position
- China’s export restrictions are a forced catalyst: The November 8th announcement shook customers who now face supply risk; they are actively seeking non-FEOC alternatives, and Neogen is the only scaled player outside China with contracted volume and advanced approvals.
- Pricing benchmark is clear: In international markets, the question is whether Neogen is the cheapest outside China, and on signed contracts, management says the answer is yes.
- Chinese overcapacity is correcting: Many Chinese producers were selling below full cost (raw material plus labor, ignoring power and fuel) and some have shut down; good-quality cell capacity is now absorbed by strong global energy storage demand, reducing pressure to dump at low prices.
- US demand runway is large: Management estimates 40–60 KTA of electrolyte salt demand for 300 GWh of US capacity by 2027, with 140–150 GWh already online; cautious customers will switch from Chinese supply by Q1/Q2 CY2026, price-conscious ones by Q3/Q4 CY2026, and all must switch by 2027.
- Local supply advantage for electrolyte: Electrolyte has a three-month shelf life with degradation, and large cell producers consume within 15 days, creating a natural moat for local manufacturers like Neogen.
Harin Kanani: "One of the biggest help China did to market our product is the restrictions they announced from 8th November. Because that really shook up the customers because at any point of time, if China comes and says, hey, I will not supply this and I will not supply that."
Morita JV & Technology Moat
- First Indo-Japan JV in battery materials: Neogen Morita New Materials Limited (NML) is formed between Neogen Ionics (minimum 80%) and Morita Investments (maximum 20%), combining Indian low cost with Japanese technology reliability.
- MUIS technology provides a process edge: Mitsubishi’s 30 years of process efficiency delivers better quality, higher productivity, and lower operating costs; the manufacturing process itself, not just raw material quality, is what gives Neogen an advantage over competitors.
- Customers welcomed the JV: Three to four large consumers are actively discussing offtake, some fast-tracked sample approvals, and two to three smaller customers have also started working; the JV gives customers peace of mind about new capacity.
- PPAP approval is a significant barrier: A leading Indian gigascale customer completed PPAP and approved the Dahej plant for long-term commercial electrolyte supply; management claims it may be the only plant in India to have achieved this, calling it equivalent to a US FDA approval.
Harin Kanani: "only we offer the combination of low cost from India with reliability from international technology for electrolyte salt, specifically LiPF6, which is seen very positively by the customers."
Base Business: Steady Despite the Fire
- Revenue grew 8% YoY to ₹209 crore: Sustained demand and higher volumes across the base and organolithium business offset the impact of Dahej plant unavailability.
- CSM contribution reached almost 16%: Very strong demand seen in the CSM segment despite the fire disruption.
- Gross margin expanded 350 bps: Gross profit improved 16%, but this did not flow through to EBITDA or PAT.
- FY26 standalone ₹850 crore plan on track: The base business target remains intact.
- FY27 base business target ₹950–1,000 crore: Full utilization expected; beyond that, without additional capex, management targets at least double-digit growth to around ₹1,150 crore.
Profitability & Fire Aftermath
- PAT squeezed to ₹3 crore: Higher operational costs, increased finance costs from debt taken for inventory and plant rebuild, continued investment in Dahej SEZ while awaiting insurance payout, initial Neogen Ionics costs, and lower Dahej utilization all weighed on the bottom line.
- Insurance premium spike: Post-renewal in July-August 2025, the premium increased significantly following the fire claim; it will stay elevated for one to two years before normalizing.
- One-time fire costs are claimable but hard to provision: Outsourcing of manufacturing stages due to lost capacity and fixed expenses at the Dahej site continue; these are recoverable under the loss-of-profit claim but difficult to accrue.
- Insurance payout timeline is staggered: The first interim payment of ₹80 crore signals claim acceptance; the stock-related claim is expected mostly in Q3 FY26; capex-related claims will be paid in stages as rebuilding progresses; the final capex payment comes after the plant is ready; the loss-of-profit claim is expected only in Q2/Q3 FY27.
- Standalone margin at full utilization (FY27): 18% plus or minus 1–1.5%, with FY28 margins improving as CSM and organolithium contribute more.
Balance Sheet & Capex
- Standalone debt rose ~₹200 crore: An NCD issuance provided liquidity for rebuilding the Dahej organic plant and ongoing growth projects until the final insurance claim is received.
- Peak debt of ₹1,800 crore expected around FY28: This coincides with the approach to full utilization; debt is variable-rate, linked to repo or MCLR, with project loans slightly higher than normal term loans.
- Debt moratorium secured: Interest payments start one year after the start of commercial production; principal repayment starts the year after that.
- Inventory elevated at ₹130-odd crore: An analyst flagged this but management did not address the reason.
- Salt capacity expansion optionality: Existing salt capacity will run out by FY28/FY29; a 2 KTA expansion is possible in 9–12 months, another 5 KTA in 15–18 months, and beyond 10 KTA would take an additional 18 months.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Battery chemicals FY26 revenue | ₹30–40 crore (revised from ₹300 crore) | FY26 |
| Battery chemicals FY27 revenue | At least ₹400–500 crore | FY27 |
| Battery chemicals FY28 revenue | More than ₹1,000 crore | FY28 |
| Battery chemicals full utilization revenue | ₹2,400–2,900 crore | FY29 |
| Base business FY26 revenue | ₹850 crore (standalone) | FY26 |
| Base business FY27 revenue | ₹950–1,000 crore (full utilization) | FY27 |
| Electrolyte salt final approvals | Customer-requested improvements complete by Jan/Feb 2026; final approval visit possible Jan/Feb 2026 | Q4 FY26 |
| Greenfield facility commercial production | Electrolyte in H1 FY27; electrolyte salt in H2 FY27 | FY27 |
| Peak debt | ~₹1,800 crore | Around FY28 |
| Standalone EBITDA margin at full utilization | 18% ± 1–1.5% | FY27 |
| Insurance stock-related claim | Majority received | Q3 FY26 |
| Insurance loss-of-profit claim | Received | Q2/Q3 FY27 |
| Rebuilt Dahej plant availability | Operational | FY27 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated revenue | ₹209 cr, up 8% YoY |
| Organic revenue | ₹184 cr, up 12% YoY |
| Inorganic revenue (Neogen Ionics) | ₹5.42 cr |
| Gross profit growth | 16% YoY, with 350 bps margin expansion |
| EBITDA | ₹30 cr |
| PAT | ₹3 cr |
| Standalone debt | ₹722 cr; net debt ₹595 cr |
| Consolidated total debt | ₹1,078 cr; net debt ₹900 cr |
| Liquid investments | ₹167 cr as on quarter end |
| Trailing 12-month DSCR | 2.1 times |
| NCDs raised | ₹200 cr via private placement |
| Battery chemicals FY26 revenue guidance | ₹30 cr to ₹40 cr, revised from earlier ₹300 cr |
| Battery chemicals FY27 revenue target | ₹400 cr to ₹500 cr |
| Battery chemicals full utilization revenue target | ₹2,400 cr to ₹2,900 cr by FY29 |
| Base business FY26 revenue plan | ₹850 cr, on track |
| Base business FY27 full utilization target | ₹950 cr to ₹1,000 cr |
| Peak gross debt expected | ₹1,800 cr, around FY28 |
| Capex completed so far | ₹620 cr; another ₹500 cr expected by year-end; total ₹1,500 cr across Dahej and Pakhajan |
| Insurance proceeds received | ₹80 cr; ~₹300 cr remaining to be received over next one year |
| Electrolyte PPAP approval | Achieved from a leading Indian gigascale customer |
| Salt provisional approval | Received from key international customer; final approval expected Q4 FY26 or Q1 FY27 |
| Neogen Ionics FY27 revenue split | ~50% electrolyte, ~50% salt |
| Standalone margin guidance FY27 | 18% plus or minus 1% to 1.5% at full utilization |
| Consolidated gross block by FY27 end | ~₹2,000 cr |
| ROCE at full utilization | 20% on a stable basis; may be lower in intermediate phase |